Tonix Pharma (TNXP) AI Stock Analysis

• Market Cap: $76.20M
• Dividend Yield: N/A
• Average Volume (3M): 1.87M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: 183.05%
• EPS Growth: -83.05%
• Country: US
• Employees: 103
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -20.56
• Shares Outstanding: 5,590,445
• 10 Day Avg. Volume: 2,550,331
• 30 Day Avg. Volume: 1,873,831
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 6.75
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: -70.17% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Tonix Pharma's overall score reflects a challenging financial position alongside promising technical momentum and strategic corporate developments. Financial struggles and valuation concerns weigh down the score, but recent positive corporate events and technical indicators suggest potential future growth opportunities.

Tonix Pharma Business Overview & Revenue Model

Company Description

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

How the Company Makes Money

Tonix Pharmaceuticals primarily generates revenue through strategic partnerships, licensing agreements, and collaborations with other pharmaceutical and biotechnology companies. By advancing its clinical-stage candidates through various stages of research and development, Tonix aims to achieve milestones that trigger payments from partners or licensees. Additionally, upon successful commercialization of its drug candidates, the company expects to earn revenue from product sales, royalties, and milestone payments. As a company in the clinical development phase, Tonix may also rely on funding from grants or government contracts to support its research efforts.

Tonix Pharma Financial Statement Overview

Summary

Tonix Pharma faces financial challenges with persistent net losses, negative EBIT and EBITDA, and a high debt-to-equity ratio. While there is some revenue growth and equity stability, profitability and cash management remain significant concerns.

Income Statement

Tonix Pharma's income statement shows a challenging financial position with consistent net losses and negative EBIT and EBITDA margins, indicating operational inefficiency. The revenue growth from zero to $11.29M TTM is a positive sign, but profitability remains a significant concern.

Balance Sheet

The balance sheet reveals a stable equity base but with a concerning debt-to-equity ratio, given the biotech industry's typical reliance on equity funding. The company's equity ratio is healthy, reflecting a low level of liabilities relative to assets, yet the overall financial health is undermined by persistent losses.

Cash Flow

The cash flow statement highlights a negative free cash flow trend, though operating cash flow shows some improvement. The high negative free cash flow relative to net income suggests cash management issues, but the company has successfully raised financing, which helps ease liquidity concerns.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
11.29M	7.77M	0.00	0.00	0.00	0.00
	Gross Profit
851.00K	3.03M	-112.09M	-92.31M	-50.51M	-28.83M
	EBIT
-82.59M	-118.38M	-112.09M	-92.31M	-50.51M	-28.83M
	EBITDA
-79.16M	-114.09M	-110.84M	-92.26M	-50.48M	-28.80M
	Net Income Common Stockholders
-135.25M	-116.66M	-116.88M	-92.29M	-52.17M	-31.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.03M	24.95M	120.23M	178.66M	77.07M	11.25M
	Total Assets
26.32M	154.46M	225.69M	240.90M	98.18M	14.56M
	Total Debt
0.00	9.81M	760.00K	956.00K	1.31M	358.00K
	Net Debt
-25.03M	-15.13M	-119.47M	-177.70M	-75.76M	-10.89M
	Total Liabilities
2.65M	48.93M	18.51M	22.18M	10.54M	5.14M
	Stockholders Equity
23.66M	105.53M	207.18M	218.72M	87.65M	9.42M
Cash Flow		Free Cash Flow
-68.46M	-109.90M	-146.20M	-110.86M	-57.13M	-26.70M
	Operating Cash Flow
-67.53M	-102.00M	-98.05M	-75.56M	-48.57M	-26.68M
	Investing Cash Flow
-215.60K	-29.07M	-48.15M	-35.31M	-8.56M	-17.00K
	Financing Cash Flow
90.89M	36.52M	87.84M	212.49M	123.11M	12.92M

Tonix Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNXP, the sentiment is Neutral. The current price of 13.41 is above the 20-day moving average (MA) of 10.51, below the 50-day MA of 20.84, and below the 200-day MA of 60.33, indicating a neutral trend. The MACD of -2.03 indicates Negative momentum. The RSI at 48.04 is Neutral, neither overbought nor oversold. The STOCH value of 56.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNXP.

Tonix Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNXP	52 Neutral	$76.20M	―	-138.69%	―	183.05%	-83.05%
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
CYCN	45 Neutral	$6.95M	―	-30.36%	―	―	86.52%
ANVS	38 Underperform	$31.18M	―	-596.70%	―	―	9.74%
XCUR	36 Underperform	$27.75M	―	-132.62%	―	-97.70%	-126.39%
EPIX	32 Underperform	$72.80M	―	-23.98%	―	―	-19.93%
KZIA	31 Underperform	$5.02M	―	-2639.52%	―	―	19.58%

Tonix Pharma Corporate Events

Tonix Pharma Announces Key Appointment and Study Timelines

Tonix Pharmaceuticals has appointed Gary Ainsworth as Vice President of Market Access, signaling potential strategic shifts in market positioning. The company also announced the expected timelines for topline data from its TNX-1300 Phase 2 study for cocaine intoxication and TNX-1500 Phase 1 study for kidney transplant rejection, marking significant steps in their product development pipeline.

Tonix Pharma Awaits FDA Decision on TNX-102 SL

Tonix Pharmaceuticals announced that the FDA has set a Prescription Drug User Fee Act goal date of August 15, 2025, for its decision on the marketing approval of TNX-102 SL, a product candidate aimed at managing fibromyalgia. This milestone could significantly impact Tonix’s market positioning and influence stakeholder expectations within the pharmaceutical industry.

Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone

Tonix Pharmaceuticals announced the FDA’s acceptance of its New Drug Application for TNX-102 SL, a non-opioid analgesic for fibromyalgia. This acceptance marks potential progress toward introducing the first new fibromyalgia drug in over 15 years, potentially reducing reliance on opioids, and signifies a significant milestone as Tonix prepares for potential market approval in 2025.

Tonix Pharma Expands Leadership Amid Drug Development

Tonix Pharmaceuticals is strategically strengthening its leadership team by appointing new executives as it prepares for significant progress with its TNX-102 SL product aimed at managing fibromyalgia. The company anticipates beginning a new study for acute stress reactions in early 2025 and awaits a potential FDA decision on its New Drug Application by August 2025. Investors are advised to consider forward-looking statements with caution due to inherent uncertainties.

Tonix Pharma Reveals Promising TNX-801 Vaccine Data

Tonix Pharmaceuticals has unveiled promising data for its TNX-801 vaccine, showing it is less virulent in immune-compromised mice compared to 20th-century vaccinia vaccines. This breakthrough suggests TNX-801 could be an effective candidate in controlling mpox spread. Investors should note the company’s forward-looking statements about product development and potential growth, while being mindful of inherent market risks.

Tonix Pharma Unveils Promising TNX-1700 Cancer Data

Tonix Pharmaceuticals Holding Corp. has unveiled new data from a manuscript showing promising results of its TNX-1700 candidate in cancer treatment. Collaborating with Columbia University scientists, the study demonstrated that TNX-1700 enhanced the effects of anti-PD-1 therapy, leading to tumor regression and prolonged survival in animal models. These findings highlight TNX-1700’s potential to revolutionize immunotherapy by targeting specific immune suppressor cells, offering hope for improved cancer treatments.

Tonix Pharma Partners for Vaccine Clinical Trial

Tonix Pharmaceuticals has partnered with the Kenya Medical Research Institute to launch a Phase I clinical trial for its TNX-801 vaccine aimed at preventing mpox and smallpox. This collaboration will see Tonix sponsoring the trial while KEMRI leads its execution, marking a significant step in vaccine development and regulatory approval processes. Investors should note that this announcement includes forward-looking statements about the company’s future operations and market potential.